CDMO Bespak, which spun out from Recipharm earlier this year, and device company H&T Presspart have announced that a new pilot-scale GMP line for filling MDIs with lower global warming potential (LGWP) propellants HFA-152a and HFO-1234ze is ready to begin manufacturing at Bespak’s Holmes Chapel, UK, site. The two companies announced in April 2024 that they had partnered on a project that would offer small-scale LGWP propellant filling of MDIs to support the transition to more sustainable inhalers.
Bespak CEO Chris Hirst commented, “The transition to low GWP propellants in pMDIs is gaining momentum around the world. At Bespak, we are proud to be at the forefront of this industry-wide initiative, and proud to partner with H&T Presspart to create further momentum. This new low GWP pilot-scale filling capability addresses the short-term market need for clinical trial supply, and will help pharma companies to advance their low GWP development programs towards commercialization. When added to our rapidly expanding low GWP commercial-scale capability, it is clear that we can now offer customers a complete transition pathway.”
H&T Presspart President Christian Krätzig said, “As the world market leader in pMDI components, H&T Presspart is committed to supporting the industry in transitioning to low GWP propellants. In our partnership with Bespak, we are now leveraging our combined expertise to create the infrastructure needed for small-scale manufacturing with low GWP propellants. The launch of a GMP pilot-scale filling line is an important step forward, and we are excited about future collaborations that will help to create a more sustainable pMDI platform for the next generation.”
Read the Bespak and H&T Presspart press release.
